Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Curevac N.V.
(NQ:
CVAC
)
3.350
+0.120 (+3.72%)
Streaming Delayed Price
Updated: 1:59 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Curevac N.V.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Dow Plummets as Fed Update, Jobless Data Weighs
June 17, 2021
The Federal Reserve's accelerated interest rate timeline and inflation forecast is putting a damper on stocks today, with worse-than-expected weekly jobless claims only adding insult to injury.
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump
June 17, 2021
Midway through trading Thursday, the Dow traded down 0.35% to 33,913.86 while the NASDAQ rose 0.73% to 14,142.60. The S&P also rose, gaining 0.07% to 4,226.52. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
34 Stocks Moving In Thursday's Mid-Day Session
June 17, 2021
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger...
Via
Benzinga
Why CureVac's Stock Is Trading Higher Today
May 13, 2021
CureVac (NASDAQ:CVAC) shares are trading higher ...
Via
Benzinga
Why CureVac Stock Is Getting Crushed Today
June 17, 2021
The biotech's COVID-19 vaccine candidate no longer appears to be viable.
Via
The Motley Fool
Exposures
COVID-19
Mid-Morning Market Update: Markets Mixed; Kroger Earnings Top Views
June 17, 2021
Following the market opening Thursday, the Dow traded down 0.29% to 33,935.28 while the NASDAQ rose 0.34% to 14,086.74. The S&P also fell, dropping 0.01% to 4,223.07. The U.S...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CureVac Stock Plummets After Covid Vaccine Fails In Interim Analysis
June 17, 2021
CureVac stock plummeted Thursday after its messenger RNA-based Covid vaccine failed in an interim analysis. The vaccine was 47% effective against Covid of any severity.
Via
Investor's Business Daily
Exposures
COVID-19
CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today
June 17, 2021
CureVac shares crashed after the German biotech said its Covid-19 vaccine was only 47% effective in preventing the disease.
Via
InvestorPlace
Exposures
COVID-19
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
June 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
25 Stocks Moving in Thursday's Pre-Market Session
June 17, 2021
Gainers Midatech Pharma plc (NASDAQ: MTP) rose 42.2% to $2.90 in pre-market trading after the company disclosed breakthrough data using Q-Sphera technology. Cellect...
Via
Benzinga
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
June 17, 2021
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its...
Via
Benzinga
Exposures
COVID-19
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent - At second interim analysis, statistical...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Unusual Options Activity Insight: CureVac
June 16, 2021
CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Wednesday. The stock price moved up to $99.74 following the option alert. Sentiment: BULLISH Option Type:...
Via
Benzinga
Moderna, BioNTech Pop Despite Mounting Pressure On Covid Vaccine Patents
June 10, 2021
The World Trade Organization is moving ahead with a plan that could waive Covid vaccine patents. But vaccine stocks weren't rattled Thursday.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
75 Biggest Movers From Yesterday
June 09, 2021
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail investor interest in the stock. NextDecade...
Via
Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
June 08, 2021
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT...
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Thor Industries Beats Q3 Estimates
June 08, 2021
Following the market opening Tuesday, the Dow traded down 0.16% to 34,574.38 while the NASDAQ rose 0.32% to 13,926.79. The S&P also fell, dropping 0.04% to 4,224.95. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Could CureVac Be a Millionaire-Maker Stock?
June 08, 2021
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in.
Via
The Motley Fool
Exposures
COVID-19
CureVac Appoints Klaus Edvardsen as Chief Development Officer
June 02, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
June 01, 2021
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data....
Via
Benzinga
Exposures
COVID-19
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
May 28, 2021
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
May 26, 2021
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
May 20, 2021
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
May 13, 2021
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-...
Via
Benzinga
Exposures
COVID-19
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
May 13, 2021
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
What's Up WIth BioNTech Stock And CureVac Stock Today?
May 10, 2021
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday’s premarket session after the company announced a Chinese joint venture to...
Via
Benzinga
70 Biggest Movers From Friday
May 10, 2021
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1...
Via
Benzinga
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
May 08, 2021
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...
Via
Talk Markets
Exposures
COVID-19
56 Stocks Moving In Friday's Mid-Day Session
May 07, 2021
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday....
Via
Benzinga
32 Stocks Moving in Friday's Pre-Market Session
May 07, 2021
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.